Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
MWN-AI** Summary
Monopar Therapeutics Inc. has made a significant strategic move by appointing Susan Rodriguez as the Chief Commercial and Strategy Officer, effective immediately. This newly established role is pivotal as the company is gearing up for the submission of a New Drug Application (NDA) for its investigational therapy ALXN1840 aimed at treating Wilson disease, anticipated in the first half of 2026. Rodriguez’s extensive experience in biopharmaceutical leadership, spanning over three decades, will play a critical role in developing Monopar's commercial strategy and infrastructure.
Chandler Robinson, CEO of Monopar, praised Rodriguez for her impressive track record in launching innovative therapies and guiding companies through growth phases, expressing confidence that her expertise will prove invaluable as ALXN1840 approaches FDA approval. Rodriguez's previous roles include Chief Operating Officer at Avadel Pharmaceuticals, where she directed the commercial strategy during the company’s acquisition by Alkermes for over $2 billion. Additionally, she has spearheaded commercial operations at Ardelyx, transforming the company into a commercial entity and successfully launching key therapeutics.
In her new role at Monopar, Rodriguez aims to build commercial capabilities to ensure broad patient access to ALXN1840, which she describes as a landmark advancement in the treatment of Wilson disease. The company, currently focusing on late-stage development and several radiopharmaceutical programs, sees this appointment as a strategic enhancement that aligns with its mission to address unmet medical needs.
Monopar Therapeutics, through this leadership expansion, demonstrates its commitment to innovation and growth in the biopharmaceutical landscape, particularly as it approaches a crucial juncture with ALXN1840.
MWN-AI** Analysis
Monopar Therapeutics' recent announcement of Susan Rodriguez's appointment as Chief Commercial and Strategy Officer is a pivotal development for the company, particularly as it gears up for its NDA submission for ALXN1840, an investigational therapy for Wilson disease. This strategic hiring reflects Monopar's commitment to building a robust commercial infrastructure to support the anticipated launch of this innovative treatment.
Rodriguez brings over 30 years of invaluable experience in biopharmaceuticals, particularly in launching therapies for rare diseases. Her previous roles, including leadership positions at Avadel Pharmaceuticals and Ardelyx, underscore her ability to drive commercial success in competitive markets effectively. This is particularly important for Monopar, which finds itself at a critical juncture. With ALXN1840 representing a significant advancement in Wilson disease therapy, Rodriguez's expertise could facilitate greater market penetration and patient access.
From an investment perspective, this leadership change signifies Monopar's proactive approach to commercialization, which is critical for companies at the clinical stage. As with any biopharmaceutical venture, the success of ALXN1840 hinges on regulatory approvals and market dynamics. Therefore, stakeholders should closely monitor the FDA's response to the NDA submission. Approval could catalyze significant interest from investors, especially given the unmet medical need in treating Wilson disease.
Moreover, potential investors should consider the broader landscape for rare disease therapeutics, which often commands premium pricing and can attract lucrative partnerships. However, investors are advised to remain cautious of the inherent risks associated with the regulatory process and competitive market entry.
In conclusion, Monopar appears well-positioned for future growth, and with Rodriguez at the helm of its commercial strategy, the company may enhance its value proposition significantly. Investors should keep a keen eye on forthcoming developments, particularly the NDA submission outcomes and market reception of ALXN1840.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical?stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company’s commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson disease.
“Susan is a highly accomplished commercial and strategic leader with a distinguished track record of successfully launching innovative rare disease therapies and guiding organizations through high-growth phases,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer. “Her experience building strong-performing commercial teams will be invaluable as Monopar advances ALXN1840 toward approval. We are very excited to welcome her to the team.”
“I am delighted to join Monopar at such a pivotal moment in its evolution,” said Ms. Rodriguez. “ALXN1840 represents the first major advancement in the treatment of Wilson disease in decades, and I look forward to building the commercial capabilities necessary to ensure broad patient access and to maximize the therapy’s impact.”
Ms. Rodriguez brings more than 30 years of biopharmaceutical leadership experience. She most recently served as Chief Operating Officer of Avadel Pharmaceuticals, where she led the company’s commercial strategy and execution, contributing to the recently completed acquisition of Avadel by Alkermes for over $2 billion. Prior to Avadel, Ms. Rodriguez was Chief Commercial Officer of Ardelyx, where she established the company’s first commercial organization and successfully transitioned Ardelyx from a development-stage company to a commercial biopharmaceutical enterprise. She led the launches of two key therapeutics, building market access, sales, marketing, and patient services capabilities and delivering strong early adoption in highly competitive areas. Before that, she served as Chief Executive Officer of Tolmar Pharmaceuticals, a specialty oncology company, where she established a new U.S. commercial entity, secured a market-leading position for its primary oncology therapy, advanced its pipeline, and successfully launched a new rare disease therapy. Earlier, she held various commercial leadership positions across multiple divisions at Abbott as well as the Abbott–Takeda joint venture, TAP Pharmaceuticals. She holds an M.S. and a B.S. in psychology, with a minor in chemistry, from the University of Pennsylvania.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease, and radiopharmaceutical programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of advanced cancers. For more information, visit: www.monopartx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: that Ms. Rodriguez will lead the Company’s commercial strategy and infrastructure build-out; that Monopar prepares for the planned submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in the first half of 2026 for ALXN1840; that Ms. Rodriguez’s experience building high-performing commercial teams will be invaluable as Monopar advances ALXN1840 toward approval; and that Ms. Rodriguez looks forward to building the commercial capabilities necessary to ensure broad patient access and to maximize the therapy’s impact. The forward-looking statements involve risks and uncertainties including, but not limited to, the following: uncertainties related to the regulatory process that Monopar intends to initiate related to ALXN1840 and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety of any products for which Monopar receives marketing approval, and Monopar’s ability to competitively market any such products as compared to larger pharmaceutical firms; Monopar’s ability to raise sufficient funds in order for the Company to support continued preclinical, clinical, regulatory, precommercial and commercial development of its programs and to make contractual milestone payments, as well as its ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, approval processes and, if applicable, commercialization; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Contact:
Monopar Therapeutics Inc.
Investor Relations
Quan Vu
Chief Financial Officer
vu@monopartx.com
Follow Monopar on social media for updates:???
X: @MonoparTx? LinkedIn: Monopar Therapeutics??
FAQ**
How does the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer impact Monopar Therapeutics Inc. MNPR's strategy for the upcoming NDA submission for ALXN1840?
What specific challenges does Monopar Therapeutics Inc. MNPR anticipate in the regulatory process for ALXN1840, and how will Ms. Rodriguez's experience address these?
Given Ms. Rodriguez's history in launching therapies, what strategies can we expect from Monopar Therapeutics Inc. MNPR to enhance market acceptance of ALXN1840 upon approval?
How will Monopar Therapeutics Inc. MNPR secure funding to support its commercial development plans under Ms. Rodriguez's leadership, especially considering the competitive landscape in rare disease therapies?
**MWN-AI FAQ is based on asking OpenAI questions about Monopar Therapeutics Inc. (NASDAQ: MNPR).
NASDAQ: MNPR
MNPR Trading
3.08% G/L:
$56.62 Last:
119,412 Volume:
$54.47 Open:
